Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-10-30 14:00 |
Alligator Bioscience utökar pipeline: Inleder preklinisk utveckling av läkemede…
|
Swedish | 195.4 KB | ||
| 2018-10-30 14:00 |
Alligator Bioscience expands pipeline: Preclinical development initiated for th…
|
English | 175.3 KB | ||
| 2018-10-26 08:00 | Swedish | 2.1 MB | |||
| 2018-10-26 08:00 | English | 2.2 MB | |||
| 2018-10-05 11:00 |
Alligator Bioscience receives government research grant
|
English | 87.1 KB | ||
| 2018-10-05 11:00 |
Alligator Bioscience erhåller forskningsanslag från Vinnova
|
Swedish | 99.0 KB | ||
| 2018-09-28 08:30 |
Nya prekliniska data stödjer goda säkerhetsegenskaper för 4-1BB-antikroppen ATO…
|
Swedish | 101.5 KB | ||
| 2018-09-28 08:30 |
New preclinical data support good tolerability properties for the 4-1BB antibod…
|
English | 107.8 KB | ||
| 2018-07-19 16:11 |
Alligator Bioscience submits application to start clinical phase I study in can…
|
English | 98.4 KB | ||
| 2018-07-19 16:10 |
Alligator Bioscience ansöker om start av klinisk fas I-studie i cancerpatienter…
|
Swedish | 99.7 KB | ||
| 2018-07-12 08:00 | Swedish | 1.1 MB | |||
| 2018-07-12 08:00 | English | 1.1 MB | |||
| 2018-06-21 08:00 |
Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, …
|
English | 107.7 KB | ||
| 2018-06-21 08:00 |
Alligator Biosciences ATOR-1017 ger kraftfull aktivering av både T-celler och N…
|
Swedish | 109.9 KB | ||
| 2018-05-08 15:00 |
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 p…
|
English | 247.6 KB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
